TopoTarget Receives Broad US and EU Patents for Key HDAC Inhibitors

25-May-2005

TopoTarget A/S announced that it has received two broad patents (US Patent No. 6888027 and European Patent No. EP 1 301 184), which strengthen the company's leading histone deacetylase (HDAC) inhibitor programme.

The US patent covers a family of Sulphonamide HDAC inhibitors including PXD101, the oncology therapy which TopoTarget is co-developing with CuraGen Corporation for the treatment of solid and haematologic cancers and which is currently in Phase II clinical trials for the treatment of multiple myeloma. The patent covers the use of TopoTarget sulphonamides in the treatment of cancer and other diseases where the inhibition of HDAC enzymes would be of benefit.

The European patent, which covers 20 European countries, covers the use of valproic acid and derivatives as HDAC inhibitors in the treatment of solid tumours. The patent is relevant to two TopoTarget oncology therapies based on valproic acid which are scheduled to enter Phase II clinical trials later this year: BACECA® for non-melanoma skin cancers and PEAC® as a suppression therapy in patients with a genetic predisposition to develop colon cancer, an indication for which PEAC® was granted Orphan Medicinal Product Designation in Europe in 2004.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances